There are 373 new prescription medicines for women in the drug pipeline, according to a recent survey of 144 companies released by the Pharmaceutical Research and Manufacturers of America.
There are 373 new prescription medicines for women in the drug pipeline, according to a recent survey of 144 companies released by the Pharmaceutical Research and Manufacturers of America.
Researchers are attacking six primary diseases: arthritis, osteoporosis, heart disease, stroke, lung cancer and breast cancer.
Arthritis affects 23 million women in the United States, costing the U.S. economy nearly $65 billion each year, according to PhRMA. Pharmaceutical companies are researching 55 new products to treat the condition, including a new class of drugs known as selective COX-2 inhibitors.
Osteoporosis affects one in four women and results in more than 1.3 million hip fractures per year. The Alliance for Aging Research estimates the annual cost of the condition to be $10 million. At least one of 27 new products for osteoporosis has the potential to build bone mass by up to 10%, PhRMA stated.
More than half of American deaths caused by heart disease and stroke occur in women. Although more men suffer strokes, more women die from them, and 44% of women who have heart attacks die, compared with only 27% of men. PhRMA's survey revealed that there are 48 new medicines in the drug pipeline for cardiovascular illness.
But pharmaceutical companies have devoted the greatest research and development energy to finding treatments for breast and lung cancers. Breast cancer affects 8 million American women and costs $10 billion per year. Lung cancer - the leading cause of cancer death among women, according to the American Cancer Society - kills an estimated 66,000 women annually.
PhRMA found that 109 products are being developed to battle breast and lung cancer. PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.